### Cure Alzheimer's Fund Closes 2008 with a Huge Win

Dear Friends,

We set out three years ago to jump start progress toward a cure for Alzheimer's disease and we are succeeding.

- The Alzheimer's Genome Project™ (AGP), targeting the full set of Alzheimer's genetic risk factors, identified 70 new genes, a tremendous result and truly breakthrough research. New genes open extensive novel scientific avenues for better understanding the disease and development of effective therapies.
- Publications announcing these results have begun and findings will continue to be announced in coming months.
- Other funded work, such as the AlzGene tool that allows researchers around the world to share and analyze information, is driving progress forward in unprecedented ways.

The personal and economic impact of Alzheimer's is enormous and the path to a cure is through research.



(L to R) Jeff Morby, Phyllis Rappaport, Jacqui Morby, and Henry McCance

Current treatments address only symptoms of the disease. Cure Alzheimer's Fund provides fast and flexible funding to outstanding researchers who pursue new high-potential ideas for effective intervention. To use a football analogy, we give researchers the opportunity to throw a 40-yard pass instead of struggling for slow gains of a few yards at a time. Our investment in the AGP allowed that kind of 40-yard pass.

Because of our AGP accomplishments, we must significantly increase funding to take advantage of important new knowledge platforms. Already, we are identifying the next ambitious goals that will push research closer to a cure.

Cure Alzheimer's Fund needs your continued support to maintain the momentum. Our urgency is heightened because Alzheimer's is the only major disease with increasing rates of mortality and 78 million baby boomers are approaching the age of high risk. We welcome your partnership. Please join us as we support research to cure this disease in our lifetime.

Best wishes for a happy and healthy holiday season,

Henry McCance, Jeff and Jacqui Morby and Phyllis Rappaport

The personal and economic impact of Alzheimer's is enormous and the path to a cure is through research.

# Major Findings Linking New Genes to Alzheimer's Disease Announced in Pu of Four Papers from the Alzheimer's Gen

Four papers published this fall in leading science journals refer to the identification of new genes that confer risk for, or protection against, Alzheimer's disease:

Bertram L and Tanzi RE. Thirty Years of Alzheimer's Disease Genetics: Systematic Meta-analyses Herald a New Era. *Nature Reviews Neurosci* 2008; 9:768-78.

Bertram L, Lange C, Mullin K, Parkinson M, Hsiao M, Hogan MF, Schjeide BM, Hooli B, DiVito J, Ionita L, Jiang H, Laird N, Moscarillo T, Ohlsen KL, Elliott K, Wang X, Hu-Lince D, Ryder M, Murphy A, Wagner SL, Blacker D, Becker KD, Tanzi RE

Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. *Am. J. Hum. Genet.* 2008; In Press.

Schjeide BM, McQueen MB, Mullin K, DiVito J, Hogan MF, Parkinson M, Lange C, Blacker D, Tanzi RE, Bertram L. Assessment of Alzheimer's disease casecontrol associations using family-based methods. *Neurogenetics* 2008; In Press.

Schjeide, B.-M.M., Hooli, B., Parkinson, M., Hogan, M.F., Divito, J., Mullin, K., Blacker, D., Tanzi, R., and Bertram, L. Follow-up of genome-wide association results suggests GAB2 as an Alzheimer's disease susceptibility gene. *Arch. Neurol.* 2008; In Press.

The genes described in these four papers are subsets of 70 AD candidate genes identified thus far by Dr. Rudy Tanzi and his colleagues at Massachusetts General Hospital as part of the Alzheimer's Genome Project™. These newly identified genes appear to function individually, or in some cases interactively, to increase or protect against risk for Alzheimer's disease. This first milestone achievement of the Alzheimer's Genome Project represents one of the most important breakthroughs in Alzheimer's research in recent history, and will greatly facilitate the development of effective therapies for the disease.

In particular, the four papers describe how newly available technology is improving understanding of the genetic mechanisms underlying the disease. The study described in the American Journal of Human Genetics is the largest genetic analysis of Alzheimer's disease carried out to date. The paper reports five DNA markers exhibiting genetic association with Alzheimer's, one of which corresponds to the gene for APOE, the only gene previously established to increase risk for late-onset Alzheimer's. Of the other four novel sites, the strongest marker was located on chromosome 14 and was further supported by an independent analysis comparing 1,400 Alzheimer's patients with healthy controls.

"The genetic association of Alzheimer's with this novel chromosome 14 gene, which like APOE appears to influence age of onset, is sufficiently strong to warrant intensive follow-up investigations into its role in the process of nerve cell death in this disease," says Tanzi. "This gene also is in the general vicinity of the presenilin-1 gene, which we know is an early-onset Alzheimer's disease gene. We don't know if that proximity is a coincidence, and we currently don't know what the new gene does, although there is some indication it may control the activity of other genes."

Another of the identified markers is in a gene known to cause spinocerebellar ataxia, a movement disorder that involves the death of nerve cells in other parts of the central nervous system, and a third is in a gene involved with the innate immune system, part of the body's defense against bacteria and viruses. The fourth marker is in a gene that produces a synaptic protein—not surprising, since it is known that loss of synapses correlates well with dementia in Alzheimer's.

"Virtually all current research into therapies is based on the Alzheimer's genes that we already know about, so each new gene we find not only enhances our ability to predict and diagnose the disease, but also provides valuable new clues about biochemical events and pathways involved in the disease process," adds Tanzi, who was

### ıblication ome Project™

a co-discoverer of all three of the known early-onset Alzheimer's genes. The team is continuing to investigate the implications of these novel genes as well as the possible impact of less strongly associated genes also identified in this study.

This is exciting, groundbreaking research that should advance our knowledge of the causes of Alzheimer's disease and guide the development of novel therapeutics to treat and prevent the disease. "This project is the most comprehensive search for the genes that cause Alzheimer's disease published to date," Tanzi said. "Our hope is to use this new information to not only better diagnose and someday predict risk for Alzheimer's, but to also learn from these genes the biological causes of Alzheimer's. The knowledge gained from understanding the Alzheimer's-associated defects in these genes will almost certainly accelerate the development of novel therapeutics and hopefully lead to a potential cure for this devastating disease." ■

## Congress Extends Charitable Gifting Program

In September Congress extended the popular charitable gifting program that allows seniors ages 70½ and older to make a tax-free contribution of up to \$100,000 from an IRA to a qualified charity. The charitable individual retirement account rollover provision was instituted in 2006 as part of the Pension Protection Act and now extends into 2009.

If you'd like to explore this as a possible way to give to Cure Alzheimer's Fund, please contact **Tim Armour, tarmour@curealzfund.org**, or **781-237-3800**.

# Our Website Got a Facelift—Check It Out

The new look includes video clips of our scientists describing their work and founders discussing the origins of Cure Alzheimer's Fund.





### **Financial Report**

#### Inception in 2004 to Date (rounded to nearest \$1,000)

Total Funds Raised	\$10,445,000	100%
Allocated for Research	\$8,212,000	<b>79</b> %
Distributed to research \$6,933,000		
Budgeted for continued research projects	\$1,279,000	

Reserve \$500,000 Administrative Expenses Paid for By Founders\* \$1,732,000 17%

#### **Current Year to Date**

Total Funds Raised \$1,836,000 Distributed to Research \$2,136,000

\* All Administrative Expenses are paid for by the organization's founders: all nonfounder donations go directly to fund research.

### Research UPDATE

To date, we have funded 20 projects in 10 major research labs.

> In 2008, we funded 11 grants, including continuing projects.

3 additional projects are pending review with planned distribution by December 31, 2008.

Visit www.curealzfund.org/research for detail on research projects.

Help us fund research with the highest probability of slowing, stopping or reversing Alzheimer's disease. Donations can be made through our website www.curealzfund.org or sent directly to our office.

For gifts of securities or direct wire transfers, please contact Tim Armour at 877-CURE-ALZ (287-3259) for further information.

#### Cure Alzheimer's FUND

34 Washington Street, Suite 300 Wellesley Hills, Massachusetts 02481 Telephone: 877-CURE-ALZ (287-3259)

Fax: 781-658-2399 www.curealzfund.org

Henry W. Oliver Building 535 Smithfield Street, Suite 625 Pittsburgh, Pennsylvania 15222 Telephone: 412-261-7191

#### Mission Statement

5%

To fund research with the highest probability of slowing, stopping or reversing Alzheimer's disease.

#### Research Consortium

Rudolph E. Tanzi. Ph.D., Chairman, Research Consortium, Harvard Medical School/ Massachusetts General Hospital

Sam Gandy, M.D., Ph.D., Mount Sinai School of Medicine

Charles Glabe, Ph.D., University of California at Irvine

David Michael Holtzman, M.D., Washington University, St. Louis

M. Ilyas Kamboh, Ph.D., University of Pittsburgh

Virginia M.-Y. Lee, Ph.D., MBA, University of Pennsylvania

Sangram S. Sisodia, Ph.D., University of Chicago

#### Scientific Advisory Board

Caleb Finch, Ph.D., University of Southern California

Paul Greengard, Ph.D., The Rockefeller University

John S. Lazo, Ph.D., University of Pittsburgh

John C. Mazziotta, M.D., Ph.D., UCLA

Marsel Mesulam, M.D., Northwestern University

#### **Board of Directors**

Jeffrey L. Morby\*, Pittsburgh, PA, Chairman

John S. Lazo, Ph.D., Pittsburgh, PA

Henry F. McCance\*, Boston, MA

Jacqueline C. Morby\*, Pittsburgh, PA

Phyllis Rappaport\*, Boston, MA

Tim Armour, Wellesley Hills, MA, President

\*Founder

#### Administration

Tim Armour, President

Katie Cutler, Director of Development

John Epeneter, Controller

Laurel Lyle, Manager, Fundraising Programs

Karen Robertson, Accountant

#### CHARITY DESIGNATION

Cure Alzheimer's Fund® is a "doing business as" name for the Alzheimer's Disease Research Foundation, a 501(c)(3) public charity with federal tax ID # 52-2396428.











#### Cure Alzheimer's Fund received gifts in honor or in memory of the following in 2008.

Abe Krame Agnes Nancy Liberio Agnes Quinton Al Liquori Allen Koering Allison Jennings McCance Alvin Schnitzer Andrea Procaccino Andrew Gehl Andrew Marten Anita Smith Ann Caudle Ann Granni Ortale Ann O'Connoi Ann Ostrovsky Ann Ryder Ann Teti Anna DiMeglio Anna Fair Anna Labetti Anne LaPorta Anne Stahley Antoinette O'Brien Antonio Tanagretta Ardell Shaw Arnold Rosen Arthur Ratner B.M. Mimms Barbara Alice Ciezki Barbara Jean Welker Beatrice Blumenson Bernadette Ritchie Bernadette Shauger Bernice Marshall Stockton Bertie Sass Beryl Sanderson

Bessie Higham

Betty Benson

Betty Hoffman

Betty Neumann

Bill Cole

Bruce Heron Aaron Alexander Welton Jr. Carmen Saienz Carol Nelson Carroll Revelle Cathleen Sedlak Cecil Hackworth Ceil Thronton Brogdon Charles Nell Charles Shorter Chester DiPronio Christine Licata Christine Weatherford Lane Claire Spatt Connie DiMostra Dalton Peck David Yeomans Delores Bauer Delores Harris Dessie Wierney Donald Berg Doris LeJeune Tenney Dorothy Liddell Dorothy Mae Smith Dorothy Scalzi Dorothy Shoytush Doug Johnson Dovie Smith Dr. Charles Heywood Dr. Samuel D. Loube Edith Kalan Edla May Sproat Edna Frances 'Tookie' Watts Edward Riley Fileen Lintz Elden Cahoon Eldora Legatski Eleanor Gelfand Eleanor Seigel Eleanor Steinwachs

Eli Dinucci Elizabeth Crowley Flizabeth Simpson Elmer Moore Elsa Schuster Flsie Narrow **Enid Douglass** Frma Bennett Ethel Bailey Ethel Mae Alexander Felicia Jackson Ferne Thorstensen Florian Lucke Frances Brickett Freida Ragni Fremont Matthews Gail Krasowski George Burnett George Joy George Loomis Georgia Mueller Gerald Hessian Germaine Arcand Gertrude Cohen Gertrude Marshall Gertrude Meade Gladys Wallach Grandma Davidson Guadalupe Sandoval Gwendolyn Forbes Hannah Wagner Hans-Ulrich Schnacke Hazel Bell Hazel M. Doleshel Helen Bright Helen Gutierrez Helen Mason Paul Helen Okazaki Helen Sweeney Henry Albers Henry Gamboa

Hilda Capo Hugh Brown Ida Bell Patrick Imogene Lewis Irene Shilling Irene Swan Isabella "Gabby" Jowett J.P. Self Jacob Bluemling James Corr James Feeney James Mahute James Van Dyck James W. Terry Jane Sutherland Janie Cangelosi Jean Fenster Jean Gallagher Jeanne Carome Jeff Oppenheim Jessie David Jesus Perez Jim MacMurray Jimmie Clark JoAn Bess Joan Fraser Joanna Brubaker Joanne Greenhouse John Dexheimer John Gibbs John Johnson John Seidlitz Joseph Young Joyce and Bob Wolff Judy Barrack June Mazzilli Kathy Donato Larrian Kilbourn Laszlo Varga Laura Veith

LaVerne Redlinger

Lawrence L. Rauch Leona Lalonde Lillian Nelson Lola Kromka Loretta Furlong Lorita Soileau Lou Voorhees Louise Opiela Lucille Marshall Lucille Williams Lyza Yu Khim Margaret Paulson Marge Youngman Marian Cuella Marie Engel Marie LeBlanc Marie Tranisi Marion Denniston Marion Rudolph Marjorie Harris Martha Flower Martha Jane Cook Mary Chaffin Mary Doughty Mary Falcioni Mary Haney Mary Jane Grimes Mary Massey Lamb Mary Mazur Mary McCully Mary Russo Mary Shaughnessy Mary Stokes Mary Weintraub Maryann Hermes Matt Matthews Maude Chikar Max Wilcox May Harwood Mercer Megan Lawley Melvin Porter

Meyer Zeicher Michael Wierney Mildred Leuterman Minnie Spence Mrs. Francis Lubin Muriel Kizelewicz Murray Goldenberg Nancy Hartman Nancy Plass Nell Lyles Olga Polcyn Ora Mae Sparks Oscar Peon Patricia Pietvrek Patsy Richardson Paula Huston Pauline David Peggy Geery Peter Henry Phyllis Kennedy Ralph Triggiano Ramona Sawyer Reese Shifflet Reese Shifflett Rex Carlile Richard Cremer Richard Gerard Schenden Richard Levin Robert Branford Robert Jones Robert Shaughness Robert Walsh Roland Pardo Ron Faherty Ron Hammond Ron Jackson Rose Ann Neves Rosemary Davillier Rosemary Johnson Roy and Milly Lamers

Ruth Ann Valenti Ruth Dovemuehle Ruth Elaine Strait Ruth Kraus Ruth Maloney Ruth Marcus Samuel Haydock Shelley Banks Shirley Poore Socorro Rodriguez Solomon Gryn Stella Smith Stelly Steinberg Sydney Cohen Sylvia Katz Terrence Briggs Thomas Caglioti Thomas Waldron Tom Gardner Toni Walters Valona Myers Velda Morby Vera Cenci Civarolo Vera Kitterman Vernon Olnev Veryl Bailey Victor and Mary Voss Violet Poole Wanda Zalasik Wilda Johnson William Harrower William Howard William J. Dayton William Taylor Willian Wentworth Yeut Ying Lee Yvonne McDonald Zetta Green



# Research Consortium Dinner

Cure Alzheimer's Fund's Research Consortium gathered Nov. 16 in Washington, D.C., for presentations on funded research and a discussion of progress in Alzheimer's disease research.

(L to R) Dr. Rudolph Tanzi, Dr. Sangram Sisodia, Dr. Virginia Lee, Dr. David Holtzman, Dr. Sam Gandy (Consortium members not pictured: Dr. Charles Glabe and Dr. Ilyas Kamboh)



Henry W. Oliver Building 535 Smithfield Street, Suite 625 Pittsburgh, Pennsylvania 15222 Presorted First-Class Mail U.S. Postage PAID Washington, DC Permit No. 13

877-CURE-ALZ (287-3259) • www.curealzfund.org







# It is critical to capitalize on recent research success.

Results of the Alzheimer's Genome Project™ are leading to better understanding Alzheimer's disease. Only by understanding the mechanisms of the disease can we get to a cure.

**DONATE TODAY** and give researchers the funding they need to end Alzheimer's disease.